Differences in Imaging Characteristics of HPV-positive and HPV-Negative Oropharyngeal Cancers: a Blinded Matched-pair Analysis
Overview
Authors
Affiliations
Background And Purpose: Human papillomavirus-positive oropharyngeal cancers typically have younger age of onset, limited tobacco exposure, and more favorable prognosis than HPV-negative oropharyngeal cancers. We assessed whether HPV-positive and HPV-negative oropharyngeal cancers have consistent differences in pretreatment imaging characteristics.
Materials And Methods: A retrospective review of 136 pretreatment CT examinations of paired HPV-positive and HPV-negative oropharyngeal cancers matched for T stage, tumor subsite, and smoking status was performed with the reviewing radiologist blinded to HPV status and clinical stage. Demographic/clinical characteristics and imaging characteristics of primary lesions and metastatic nodal disease were compared by use of Fisher exact testing. The McNemar χ(2) test was used for the matched-pair analysis.
Results: By imaging, HPV-negative tumors were more likely to demonstrate invasion of adjacent muscle (26% versus 6%, P = .013). HPV-positive primary tumors were more likely to be enhancing and exophytic with well-defined borders, whereas HPV-negative primary tumors were more likely to be isoattenuated and demonstrate ill-defined borders, though these results were not statistically significant. HPV-positive tumors were more likely to demonstrate cystic nodal metastases than HPV-negative tumors (36% versus 9%, P = .002).
Conclusions: In this matched and blinded analysis of the imaging differences between HPV-positive and HPV-negative oropharyngeal cancers, HPV-positive carcinomas often had primary lesions with well-defined borders and cystic nodal metastases, whereas HPV-negative primaries more often had poorly defined borders and invasion of adjacent muscle.
Suto T, Kawaguchi M, Kato H, Shibata H, Ogawa T, Ando T J Clin Med. 2025; 14(3).
PMID: 39941703 PMC: 11818298. DOI: 10.3390/jcm14031027.
The radiological features of HPV-positive vs HPV-negative OPSCC at a South African hospital.
Naranbhai A, Afrogheh A, OHagan S, Grobbelaar J, van Rensburg L SA J Radiol. 2024; 28(1):2976.
PMID: 39650704 PMC: 11621980. DOI: 10.4102/sajr.v28i1.2976.
Chen L, Lauwers I, Verduijn G, Philippens M, Gahrmann R, Capala M Cancers (Basel). 2024; 16(11).
PMID: 38893224 PMC: 11171338. DOI: 10.3390/cancers16112105.
The potential use of therapeutics and prophylactic mRNA vaccines in human papillomavirus (HPV).
Movahed F, Darzi S, Mahdavi P, Mahdi M, Allela O, Sameer H Virol J. 2024; 21(1):124.
PMID: 38822328 PMC: 11143593. DOI: 10.1186/s12985-024-02397-9.
Amato M, Santonocito S, Bruno M, Polizzi A, Mastroianni A, Chaurasia A Heliyon. 2024; 10(10):e31061.
PMID: 38813162 PMC: 11133762. DOI: 10.1016/j.heliyon.2024.e31061.